Year: 2021
Notes from the 2021 HRA Expert Panel Discussion “Are Standard Hepatocyte Models/Test Systems Still Good Enough?”
MicroPhysiological Systems (MPS) is a general term used to describe miniaturized, in vitro test systems that couple microfluidics with advanced...
Meet the Scientists: Program Execution
In this installment of our Meet the Scientist series, we asked several members from various areas of our Program Execution...
Interesting Topics at the 3rd SCI-RSC Symposium on Transporters in Drug Discovery and Development
A recap of some of the important and promising research that was presented at the Transporters in Drug Discovery and Development symposium...
Meet the Scientists: Analytical Services’ Chandra Kollu & Nadya Galeva
This month we’re featuring two of the experts in our analytical services department: Senior Scientist Chandra Kollu and Mass Spectrometry...
ADME/PK & DDI Best Practices Industry Survey Results & Infographic
With over 3500 respondents, only 4% of respondents said they had never experienced any repercussions from postponing these studies...
Guide to When & Why to Evaluate ADME/DMPK & Drug-Drug Interactions Available
In Safety first: Assessing drugs early can preclude regulatory and health issues, a new ebook developed by a collaboration with...
Meet the Scientist: Darina Hynes
Dr. Darina Hynes obtained her Ph.D. in Molecular Medicine from the Royal College of Surgeons in Ireland. She is currently a...
Why Switch to Hepatocyte Pellets?
You may have heard about the patented CryostaX® format of hepatocyte pellets, but do you know why XenoTech and countless other researchers have made the…
Four Ways CROs Drive Innovation for Improved In Vitro Drug Metabolism and Pharmacokinetics (DMPK) Studies
Agility and focused growth allow drug developers to outsource expertise and benefit the industry at-large by fostering innovation. Panelists at the 2021 Annual DMDG Meeting…
DDI & Drug Repurposing Article featured in Drug Discovery World (DDW) Spring Edition 2021
Repurposing (repositioning, re-profiling, or re-tasking) a drug potentially saves years of costly testing from going to waste and potentially providing a higher chance of success.…
Improve the Value of Your Molecule's Testing with Expert Insight
Our expert team of DDI and drug metabolism consultants can help you piece together the data for a successful data package that meets regulatory expectations for thorough risk assessment of a new or repurposed compound
Read our Follow-Up Interview in Outsourcing Pharma
Find the Q&A between Director of Scientific Consulting, Dr. Maciej Czerwinski, and the editorial team at Outsourcing Pharma for more answers about how DDI testing and data interpretation adds value to the drug repurposing process
